Literature DB >> 21288720

Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.

Veronique Lorgis1, Marie Paule Algros, Cristian Villanueva, Loic Chaigneau, Antoine Thierry-Vuillemin, Thierry Nguyen, Martin Demarchi, Fernando Bazan, Jean Loup Sautiere, Yolande Maisonnette-Lescot, Frederic Ringenbach, Patrick Bontemps, Xavier Pivot.   

Abstract

The aim of the present study was to compare the tumour grade, Estrogen Receptor (ER), Progesteron Receptor (PgR) and Human Epidermal Receptor-2 (HER-2) status in the core needle biopsy (CNB) with those observed in the subsequent excisional primary tumour (EPT). All patients diagnosed with an early breast cancer in our University Hospital Center between January 1, 2005 and December 31, 2006 were included but exclusion criteria of patients with large tumour requiring neoadjuvant chemotherapy and cases with more than one tumour (multicentricity/multifocality tumours). Histological tumour grade assessed according to Nottingham Grading System (SBRm), ER, Pgr and HER-2 tumoural status were assessed twice in CNB and in EPT. A total of 175 patients were assessed. The concordance between CNB and EPT for Grade, ER, PgR and HER2 status were 75.4% (p > 0.00001), 84% (p > 0.00002), 78.3% (p = 0.002) and 98.3% (p = 0.486) respectively. In conclusion CNB can be used with confidence for HER2 determination. For grade, PgR and ER due to substantial discordance results from CNB should be used with caution.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21288720     DOI: 10.1016/j.breast.2010.12.007

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  20 in total

Review 1.  Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

Authors:  Armand de Gramont; Sarah Watson; Lee M Ellis; Jordi Rodón; Josep Tabernero; Aimery de Gramont; Stanley R Hamilton
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

2.  Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases.

Authors:  Jie Chen; Zu Wang; Qing Lv; Zhenggui Du; Qiuwen Tan; Di Zhang; Bingjun Xiong; Helin Zeng; Juxiang Gou
Journal:  Pathol Oncol Res       Date:  2017-01-10       Impact factor: 3.201

3.  In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?

Authors:  Xavier Pivot; Laura Mansi; Loic Chaigneau; Philippe Montcuquet; Antoine Thiery-Vuillemin; Fernando Bazan; Erion Dobi; Jean L Sautiere; Frederic Rigenbach; Marie P Algros; Steve Butler; Farid Jamshidian; Phillip Febbo; Christer Svedman; Sophie Paget-Bailly; Franck Bonnetain; Christian Villanueva
Journal:  Oncologist       Date:  2015-03-20

4.  Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.

Authors:  Ji Hyun Youk; Eun Ju Son; Jin Chung; Jeong-Ah Kim; Eun-Kyung Kim
Journal:  Eur Radiol       Date:  2012-04-17       Impact factor: 5.315

5.  Accuracy of prognostic and predictive markers in core needle breast biopsies compared with excisional specimens.

Authors:  Mohammad Motamedolshariati; Bahram Memar; Mohsen Aliakbaian; Mohammad T Shakeri; Mohammad Samadi; Ali Jangjoo
Journal:  Breast Care (Basel)       Date:  2014-05       Impact factor: 2.860

6.  Concomitant use of 18F-FDG PET-CT SUVmax is useful in the assessment of Ki67 labeling index in core-needle biopsy specimens of breast cancer.

Authors:  Hiroki Nakajima; Kazuma Maeno; Tokiko Ito; Toshiharu Kanai; Takaaki Oba; Mayu Ono; Fumiyoshi Takayama; Tsuyoshi Uehara; Ken-Ichi Ito
Journal:  Gland Surg       Date:  2021-01

7.  Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response.

Authors:  Rinath M Jeselsohn; Lillian Werner; Meredith M Regan; Aquila Fatima; Lauren Gilmore; Laura C Collins; Andrew H Beck; Shannon T Bailey; Housheng Hansen He; Gilles Buchwalter; Myles Brown; J Dirk Iglehart; Andrea Richardson; Steven E Come
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

8.  Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer.

Authors:  Xiaosong Chen; Long Sun; Yan Mao; Siji Zhu; Jiayi Wu; Ou Huang; Yafen Li; Weiguo Chen; Jianhua Wang; Ying Yuan; Xiaochun Fei; Xiaolong Jin; Kunwei Shen
Journal:  BMC Cancer       Date:  2013-08-19       Impact factor: 4.430

9.  Personalized medicine - where do we stand? Pouring some water into wine: a realistic perspective.

Authors:  Ursula Gundert-Remy; Aleksandar Dimovski; Srećko Gajović
Journal:  Croat Med J       Date:  2012-08       Impact factor: 1.351

10.  Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?

Authors:  Sanjoy Chatterjee; Animesh Saha; Indu Arun; Sonali Susmita Nayak; Subir Sinha; Sanjit Agrawal; Mayur Parihar; Rosina Ahmed
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.